Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for QR-1123 evaluating safety and tolerability in autosomal dominant retinitis pigmentosa due to P23H RHO mutation; studying Phase 1/Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Retinitis Pigmentosa

Drugs mentioned

• QR-1123

Snippet

Sponsor: ProQR Therapeutics | Conditions: Autosomal Dominant Retinitis Pigmentosa, Eye Diseases | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING